Cover Image
Market Research Report

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 374384
Published Content info 60 Pages
Delivery time: 1-2 business days
Price
Back to Top
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Pipeline Review, H2 2018
Published: September 11, 2018 Content info: 60 Pages
Description

Summary:

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 10 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively.

Report covers products from therapy areas Cardiovascular, Genito Urinary System And Sex Hormones, Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System and Metabolic Disorders which include indications Arterial Thrombosis, Renal Failure, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Emphysema, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Hepatic Veno-Occlusive Disease, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Metastatic Lung Cancer, Multiple Sclerosis, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Pulmonary Fibrosis, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Thrombosis, Thrombotic Microangiopathy and Venous (Vein) Thrombosis.

The latest report Plasminogen Activator Inhibitor 1- Pipeline Review, H2 2018, outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
  • The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1656TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview
    • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development
    • CisThera Inc
    • Jazz Pharmaceuticals Plc
    • MDI Therapeutics Inc
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles
    • Bispecific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • defibrotide sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SK-216 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PAI1 for Immunology, Respiratory and Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5484 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5614 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Dormant Products
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued Products
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 23, 2018: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
      • Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Defitelio at ASH 2017 Annual Meeting
      • Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
      • Nov 07, 2016: Jazz Pharmaceuticals to Present New Data on Defitelio at the Annual ASH Meeting
      • Aug 02, 2016: CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation
      • Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow
      • Mar 30, 2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update
      • Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting
      • Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD
      • Sep 30, 2015: Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease
      • Feb 12, 2015: Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease at BMT Tandem Meetings
      • Dec 11, 2014: Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease
      • Dec 02, 2014: Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting
      • Mar 31, 2014: Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease
      • Dec 11, 2013: Interim Results From Gentium's Treatment IND for Defibrotide and Additional Data on Defibrotide in the Prevention of Acute Graft Versus Host Disease Presented at the American Society of Hematology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indications, H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by CisThera Inc, H2 2018
  • Pipeline by Jazz Pharmaceuticals Plc, H2 2018
  • Pipeline by MDI Therapeutics Inc, H2 2018
  • Dormant Products, H2 2018
  • Dormant Products, H2 2018 (Contd..1), H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top